AndroGel Sales Continue to Slope in Third Quarter, AbbVie Reports
Sales of AndroGel, a drug blamed for serious injuries in hundreds of testosterone lawsuit claims, dropped nearly 7% in the third quarter, according to its manufacturer’s most recent earnings report.
Among other things, AbbVie Inc.’s recent numbers reflect a slowing demand for the hormone-raising prescription therapy, which earned the company $232 million over three months. The 6.7% decline, from the same quarter last year, follows a similar loss of 15.6% in the second quarter of 2014. Around that time, concerns about AndroGel’s safety began to surface with a groundbreaking study published in JAMA: The Journal of the American Medical Association. Findings of the study revealed an increased risk of heart attacks, strokes, and other life-threatening cardiovascular injuries in men taking a prescription testosterone therapy belonging to a class designed to treat “Low T,” a condition drug manufacturers categorize by certain issues common to aging. These may include but are not limited to fatigue, sexual dysfunction and low libido. In January 2014, the medical journal PLoS One found that AndroGel and similar medications may double the risk for heart attacks in younger men with a pre-existing history of heart disease, and all men over 65.
FDA Issues Warning about Testosterone Heart Attacks, Strokes
After the U.S. Food and Drug Administration (FDA) caught wind of these findings, a public health warning was announced to note the possible association between “Low T” drugs and the risk for cardiovascular side effects. Medications specified in the warning include AndroGel, AndroDerm, Axiron, Testim and Depo-Testosterone, among others.
In the months since these products were flagged for possible danger, they have been named in more and more testosterone lawsuits. In a federal litigation currently underway in the U.S. District Court, Northern District of Illinois, at least 223 lawsuits had been filed on behalf of individuals who allegedly suffered serious cardiovascular injuries. Plaintiffs in these cases accuse AbbVie and other companies of failing to provide adequate warning about the possible risks of their testosterone treatments, which were designed defectively. They also allege that drug manufacturers promoted “Low T” medications for off-label uses not approved by the FDA, which, as a result led to thousands of men being unknowingly placed at risk for side effects.
Considering a Testosterone Lawsuit? Call Bernstein Liebhard LLP.
Contact our Firm today for more information about how to file a testosterone lawsuit against the makers of AndroGel or another product. Call us now at (877) 779-1414.